We are live on ! Find out more
MNPR icon

Monopar Therapeutics
MNPR

7 hedge funds and large institutions have $429K invested in Monopar Therapeutics in 2020 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more funds holding

Funds holding: 6 → 7 (+1)

6% more capital invested

Capital invested by funds: $403K → $429K (+$26K)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

0.02% less ownership

Funds ownership: 0.14% → 0.12% (-0.02%)

Holders
7
Holders Change
+1
Holders Change %
+16.67%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$13.9K
2
UBS Group
UBS Group
Switzerland
+$4.9K
3
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors
North Carolina
+$878
4
Wells Fargo
Wells Fargo
California
+$26

Top Sellers

Rank Fund Capital Flow
1
Northern Trust
Northern Trust
Illinois
-$30.7K
2
TRCT
Tower Research Capital (TRC)
New York
-$17K

MNPR Hedge Fund Activity: Q4 2020 in Review

7 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Monopar Therapeutics (MNPR) for Q4 2020, worth a combined $429K — up 6.5% from $403K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new MNPR positions and 0 closed out — a net gain of 2 holders — while 2 added to existing stakes and 2 trimmed.

The largest buyer was BlackRock, adding an estimated $13.9K. The largest seller was Northern Trust, cutting an estimated $30.7K.

  • 7 institutional investors held Monopar Therapeutics (MNPR) as of Q4 2020, up from 6 in Q3 2020.
  • Funds reported $429K of Monopar Therapeutics stock for Q4 2020, up 6.5% quarter-over-quarter.
  • 2 funds opened new Monopar Therapeutics positions in Q4 2020 and 0 closed out, a net change of +2 holders.
  • The largest Monopar Therapeutics buyer in Q4 2020 was BlackRock, an estimated $13.9K added.
  • The largest Monopar Therapeutics seller in Q4 2020 was Northern Trust, an estimated $30.7K sold.

Based on aggregated 13F filings for Q4 2020.